Ifosfamide-containing regimens for treating patients with osteosarcomas.

Abstract

BACKGROUND:

This systemic analysis was conducted to evaluate the efficacy and safety of an ifosfamide- containing regimen in treating patients with osteosarcoma.

METHODS:

Clinical studies evaluating the efficacy and safety of Ifosfamide-containing regimen on response and safety for patients with osteosarcoma were identified by using a predefined search strategy. Pooled response rate (RR) of treatment were calculated.

RESULTS:

When ifosfamide-containing regimens were evaluated, 4 clinical studies which including 134 patients with osteosarcoma were considered eligible for inclusion. Systemic analysis suggested that, in all patients, pooled RR was 44.8% (60/134) in ifosfamide-containing regimens. Major adverse effects were neutropenia, leukopenia, and fatigue inIfosfamide-containing regimens; No treatment related death occurred in cantharidin combined regimens.

CONCLUSION:

This systemic analysis suggests that ifosfamide-containing regimens are associated with good response rate and acceptable toxicity in treating patients with osteosarcoma, but this result should be confirmed by randomized clinical trials.

• Authors: Yan-Yan Li, Xiao-Ming Jiang, Yi-Guo Dong, Gang Xu, Yu-Bo Ma
• Journal: Asian Pacific journal of cancer prevention : APJCP (Asian Pac J Cancer Prev) Vol. 15 Issue 22 Pg. 9763-6 ( 2014) ISSN: 2476-762X [Electronic] Thailand
• PMID: 25520101 (Publication Type: Journal Article)

Chemical References

• Epirubicin
• Cisplatin
• Ifosfamide

Topics

• Adolescent
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Bone Neoplasms (drug therapy, mortality, pathology)
• Cisplatin (administration & dosage)
• Epirubicin (administration & dosage)
• Follow-Up Studies
• Humans
• Ifosfamide (administration & dosage)
• Neoplasm Recurrence, Local (drug therapy, mortality, pathology)
• Neoplasm Staging
• Osteosarcoma (drug therapy, mortality, pathology)
• Prognosis
• Survival Rate